Intranasal human growth hormone (hGH) induces IGF-I levels comparable to subcutaneous injection with lower systemic exposure to hGH in healthy volunteers.
Affiliation
Critical Pharmaceuticals Limited, BioCity Nottingham, Pennyfoot St, NottinghamIssue Date
2015-10-01
Metadata
Show full item recordAbstract
The development of an improved, efficacious hGH product administered by a non-injectable route of delivery such as the nasal route is highly desirable. We have developed a novel nasal hGH product (CP024) that showed excellent nasal absorption in animal models, however translation of these results into the clinical setting is essential, as past attempts to develop such formulations by other groups have been unable to induce IGF-1 in man.Citation
Intranasal human growth hormone (hGH) induces IGF-I levels comparable to subcutaneous injection with lower systemic exposure to hGH in healthy volunteers. 2015:jc20144146 J Clin Endocrinol MetabJournal
Journal of Clinical Endocrinology and MetabolismDOI
10.1210/jc.2014-4146PubMed ID
26425883Type
ArticleLanguage
enISSN
1945-7197ae974a485f413a2113503eed53cd6c53
10.1210/jc.2014-4146
Scopus Count
Collections
Related articles
- Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
- Authors: Laursen T, Grandjean B, Jørgensen JO, Christiansen JS
- Issue date: 1996 Sep
- A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
- Authors: Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M
- Issue date: 2014 Oct
- Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects.
- Authors: Brimhall DB, Petri N, D'Angelo P
- Issue date: 2018 May
- Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men.
- Authors: Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T
- Issue date: 2000 Feb
- Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
- Authors: Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, Rosenfeld RG, Zadik Z, Jaron-Mendelson M, Koren R, Amitzi L, Raduk D, Hershkovitz O, Hart G
- Issue date: 2017 May 1